OXI-4503 is under clinical development by Oncotelic Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OXI-4503’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OXI-4503 (combretastatin A1 di-phosphate / CA1P) is under development for the treatment of relapsed and refractory acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). The drug candidate is administered as intravenous infusion.is. The drug candidate is developed based on Vascular Disrupting Technology. The drug candidate was under development for primary or secondary hepatic tumor burden and advanced solid tumors. The drug candidate acts by targeting Tubulin.
Oncotelic Therapeutics overview
Oncotelic Therapeutics, Inc. (OTI) is a pharmaceutical and healthcare company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting agents. OTI is developing a product for treatment of anaplastic thyroid cancer, medullary thyroid cancer, stage IV papillary thyroid cancer, ovarian cancer, stage IV follicular thyroid cancer, and others. OTI offers development pipeline such as CA4P and Oxi4503. The company also conducts multiple clinical trials in oncology to discover small-molecule anticancer agents belong to benzosuberene class of compound. It operates through researchers in the University of Florida and the University of Arhus on anti-angiogenic and anti-metastatic agents. Oxigene is headquartered in South San Francisco, California, the US.
For a complete picture of OXI-4503’s drug-specific PTSR and LoA scores, buy the report here.